Health
Medical
Cancer Prevention
VolitionRX
$3.289876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.10 (-3.10%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell VolitionRX and other stocks, options, ETFs, and crypto commission-free!
About
VolitionRX Limited Common Stock, also called VolitionRX, is a multi-national life sciences company. It engages in the development of blood-based cancer tests to help diagnose a range of cancers. Read More Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Singapore.
Employees
44
Headquarters
Singapore, Central Singapore
Founded
2010
Market Cap
128.00M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
89.33K
High Today
$3.38
Low Today
$3.23
Open Price
$3.38
Volume
13.05K
52 Week High
$3.63
52 Week Low
$1.44
Collections
Health
Medical
Cancer Prevention
Asia (Non-China)
Asia
News
Yahoo FinanceApr 24
VNRX: Entry Into China, Taiwan Large Lung Cancer Study and Animal Diagnostics Subsidiary
By Brian Marckx, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT Capital Markets Day Update Following reporting of Q4 earnings in mid-March, VolitionRx (VNRX) had a spate of news leading up to their ‘Capital Markets Day on April 9th at the New York Stock Exchange. The news is an extension of the product development related updates provided during the Q4 earnings call, which as a reminder, included new (i.e. initial) ‘proof-of-concept’ study data from the first round of ‘product grade’ assays in...
Price Paid on Robinhood
6% Higher
Right Now
52 Week Low
$1.44
Average Price Paid
$3.09
52 Week High
$3.63
Earnings
-$0.17
-$0.15
-$0.13
-$0.11
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
-$0.12 per share